Jake Becraft, the founder of Strand Therapeutics, laid down a distinction that should haunt any ambitious builder in deep tech: the difference between a 'good drug' and a 'good product.' A good drug, Becraft says, simply works for an individual. It helps them. But a good product? That's about getting medicine to people at scale, plugging into existing infrastructure, and being economically viable for a broad population.

He hammered this home with a brutal example: a cell therapy costing $750,000 just to manufacture, requiring three months of time. “That's a bad product,” he said, even if it helps someone. The fundamental cost of goods sold (COGS) makes it unsustainable for wide impact. Becraft argues that for maximum impact, you need to make solutions that seamlessly integrate into the systems we already have.

For genetic medicine, this means cracking the "holy grail" of IV-administered systemic delivery beyond the liver. The industry has made strides in liver-specific treatments, but getting therapies to other parts of the body via the bloodstream remains the unsolved challenge. Solving this isn't just a science problem; it's a product-market fit problem in healthcare.

Key Takeaways

  • There's a chasm between a 'good drug' (it works) and a 'good product' (it's scalable, accessible, and affordable for many). Don't confuse the two.
  • High COGS and lengthy manufacturing times, like the $750,000, three-month cell therapy Becraft mentioned, render even effective treatments largely unscalable, making them a "bad product."
  • To have the broadest impact, your innovation must be designed to integrate into existing delivery infrastructure, not demand an entirely new one.
  • The biggest hurdle in genetic medicine isn't just discovery, but achieving IV systemic delivery beyond liver-specific applications, a challenge Becraft calls the "holy grail."
  • Becraft's team at Strand Therapeutics focused on solving this systemic delivery problem, encapsulated in the "Genetic Medicine Development Paradox."

The Genetic Medicine Development Paradox

This 'joke' highlights the historical bottleneck in genetic medicine, where significant progress has been made in treating liver-specific conditions, but the challenge of systemic delivery to other organs remains largely unsolved, preventing broad application of these therapies.

  • Step One: Prove it works in the liver.
  • Step Two: Question mark (how to get beyond the liver and treat other diseases).
  • Step Three: We'll treat all these diseases / Profit.

When This Works (and When It Doesn't)

This framework perfectly captures the state of genetic medicine over the last few decades. It highlights that the most celebrated breakthroughs often solve the easiest part first (liver delivery), leaving the much harder, more impactful problem of systemic delivery as a looming "question mark." This 'paradox' works when you're looking at broad disease impact and patient populations, where scalable delivery is as critical as the therapy's efficacy. It applies to any field where an initial, limited success gets prematurely celebrated while a foundational, systemic barrier remains.

Where it might not apply as strictly is in extremely rare, ultra-orphan diseases where any effective treatment, regardless of cost or delivery complexity, is a life-saving miracle. In those cases, the immediate need outweighs broad scalability concerns. However, even then, the long-term goal for broader access still points back to Becraft's distinction.

What to Do With This

Pull your next big idea out of your head. Whether it's a deep-tech SaaS platform or a hardware innovation, don't just ask if it works (your "good drug"). Ask if it's a "good product" from day one. Map out your equivalent of the Genetic Medicine Development Paradox. What's your "Step One" — the easiest, most contained problem it solves? What's your "Step Two" — the fundamental delivery or scaling challenge that's currently a giant question mark? Before you even think about "Step Three" (treating all diseases / profit), dedicate a week to intensely brainstorming solutions for that "Question mark." Can you design the core technology or business model to plug into existing customer behaviors or distribution channels? Don't let discovery blind you to delivery.